Genvor Announces Issuance of New U.S. Patent for Corn with Antifungal Peptide

Core Insights - Genvor, Inc. has been granted U.S. Patent No. 12,458,684 for transgenic corn expressing antifungal peptide AGM182, aimed at combating fungal infections in maize [1][2][3] Company Overview - Genvor is focused on AI-accelerated peptide technology for sustainable agriculture, utilizing its proprietary BioCypher™ Algorithm to design next-generation antimicrobial peptides [1][6] - The company aims to provide scalable agricultural solutions that enhance crop protection and optimize agricultural outcomes [6] Patent Details - The patent covers biological compositions that reduce Aspergillus flavus, a fungal pathogen that produces aflatoxins, which can contaminate corn and other crops [2][4] - Research indicates that the technology also shows activity against other mycotoxin-producing fungi, including those from Fusarium species [2][4] Economic Impact - Economic losses from fungal diseases in corn in the U.S. are estimated between $3 billion to $5 billion annually, considering yield reductions and quality degradation [3] - Aflatoxin contamination can lead to market impacts ranging from approximately $52 million in lower-risk years to as much as $1.68 billion in high-risk years [3] Research Validation - Published research validates the effectiveness of AGM182 in transgenic corn seeds, demonstrating a 76–98% reduction in total aflatoxin contamination without adverse effects on plant growth or yield [5][7] - The technology reflects decades of foundational research and aims to deliver safe and effective peptide technologies for global agriculture [5]